Closing Thoughts on Research into the Induction of Fetal Hemoglobin by FTX6058
Pharmacy Times® interviewed Christopher Moxham of Fulcrum Therapeutics, on his closing thoughts on the research he conducted into the induction of fetal hemoglobin by FTX6058.
Pharmacy Times® interviewed Christopher Moxham, the senior vice president of discovery research at Fulcrum Therapeutics, on his presentation at the 62nd ASH Annual Meeting and Exposition. The presentation discusses research into the induction of fetal hemoglobin by FTX6058, a novel small molecule development candidate.
In this video, Moxham notes some closing thoughts on his research into the induction of fetal hemoglobin by FTX6058.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- Iberdomide May Aid Efficacy of CAR T-Cell Therapy in Multiple Myeloma
September 19th 2025